We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
178 result(s) found, displaying 31 to 40
-
Prescription medicine registrationActive ingredients: Ipilimumab.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for REBLOZYL luspatercept 25 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for REBLOZYL luspatercept 75 mg powder for injection vial.
-
Prescription medicine decision summarySotyktu (deucravacitinib) is approved to treat plaque psoriasis.
-
Prescription medicine registrationActive ingredients: deucravacitinib.
-
Prescription medicine decision summaryCamzyos (mavacamten) is approved to treat cardiomyopathy.
-
Prescription medicine registrationActive ingredients: nivolumab, relatlimab.
-
Prescription medicine registrationActive ingredients: mavacamten.